Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC-2022-1000x250

Click on the links below to access the Industry Sponsored Satellite Symposia Invitations. 

Tailoring Therapy: Emerging Treatment Options in NSCLC

01-Tailoring-Therapy-Emerging-Treatment-Options-in-NSCLC-MIRATI-Thumb

Wednesday, 11:30 – 13:00
View the satellite invitation

Targeting KRASG12C: A New Era for Patients with Advanced NSCLC

02-Targeting-KRASG12C-A-New-Era-for-Patients-With-Advanced-NSCLC-AMGEN-Thumbnails

Wednesday, 11:30 – 13:00
View the satellite invitation

Breaking Barriers in Thoracic Cancers: The Expanding Possibilities for Patients With I-O Treatment

03-Breaking-Barriers-in-Thoracic-Cancers-BMS-Thumb

Wednesday, 18:15 – 19:45
View the satellite invitation

Novel Therapies for EGFR Exon 20 Insertions and ALK-Positive NSCLC: Developments and Implications

04-Novel-Therapies-for-EGFR-Exon-20-Insertions-and-ALK-Positive-NSCLC-TAKEDA-Thumb

Wednesday, 18:15 – 19:45
View the satellite invitation

Evolving Treatment Options and Practices in EGFR-Mutant NSCLC

07-Spotlight-on-Emerging-Therapies-for-Patients-with-EGFR-positive-NSCLC-JANSSEN-Thumb

Thursday, 13:30 – 15:00
View the satellite invitation

CNS Disease Management in EGFRm NSCLC

07-CNS-Disease-Management-in-EGFRm-NSCLC-ASTRAZENECA-Thumb

Thursday, 13:30 – 15:00
View the satellite invitation

Management of Patients with Oncogene-Driven NSCLC: The Shift Towards Personalized Medicine

08-Management-of-Patients-with-METex14-NSCLC-The-Shift-Towards-Personalized-Medicine-NOVARTIS-Thumb

Thursday, 18:15 – 19:45
View the satellite invitation

Enabling Future Improvements in Cancer Care With Fast Next-Generation Sequencing (NGS) Results

09-Enabling-Future-Improvements-in-Cancer-Care-With-Fast-Next-Generation-Sequencing-NGS-Results-THERMO-FISHER-Thumb

Thursday, 18:15 – 19:45
View the satellite invitation

Unresectable Stage III NSCLC: No Patients Left Behind

10-Unresectable-Stage-III-NSCLC-No-Patients-Left-Behind-ASTRAZENECA-Thumb

Friday, 12:45 – 14:15
View the satellite invitation

TTFields: A Potential Innovative Treatment Modality in Lung Cancer

11-TTFields-A-Potential-Innovative-Treatment-Modality-in-Lung-Cancer-NOVOCURE-Thumb

Friday, 12:45 – 14:15
View the satellite invitation

Quantity Versus Quality of Life in Advanced NSCLC Patients Treated with Immunotherapy

12-Quantity-Versus-Quality-of-Life-in-Advanced-NSCLC-Patients-Treated-With-Immunotherapy-SANOFI-Thumb

Friday, 18:45 – 20:15
View the satellite invitation

Evolving Immuno-Oncology Treatment Paradigm in NSCLC

13-Evolving-Immuno-Oncology-Treatment-Paradigm-in-NSCLC-MSD-Thumb

Friday, 18:45 – 20:15
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.